Darbepoetin

Phase 3Small molecule

Bayer

Darbepoetin is one of 170 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

169

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

HypertensionActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

NeurocognitiveCompleted

NephropathyActive, not recruiting

CirrhosisActive, not recruiting

Liver TransplantPhase 3

Active, not recruiting

HypertensionPhase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 2/Phase 3

Active, not recruiting

NeurocognitivePhase 3

Completed

NephropathyPhase 2/Phase 3

Active, not recruiting

CirrhosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Darbepoetin

Bayer

Phase 3

1 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Edarbi

Takeda

Preclinical

4 5

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 6

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 9

Avastin

BBio-Thera Solutions

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Liver Transplant

NCT07169643

Q4 2031

N/ANot yet recruiting

Cirrhosis

NCT07131280

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes2 trials

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Unknown status·SSt. Bartholomew's Hospital·Phase 2/3·NCT00234143·360 enrolled

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Unknown status·GGroupe Francophone des Myelodysplasies·Phase 2·NCT00443339·99 enrolled

Cirrhosis2 trials

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07131280·110 enrolled

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07002827·60 enrolled

Dialysis1 trial

Long-term Pre-dialysis Extension in Europe and Asia Pacific

Completed· Bayer logo

Bayer·Phase 2·NCT02055482·166 enrolled

Liver Transplant1 trial

Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)

Recruiting·FFundacion Clinic per a la Recerca Biomédica·Phase 3·NCT07169643·140 enrolled

Nephropathy1 trial

Effect of Darbepoetin in Contrast-induced Nephropathy

Terminated·SSeoul National University Bundang Hospital·Phase 2/3·NCT01197235·80 enrolled

2 more indications

Hypertension1 trial

Mechanisms of EPO-induced Hypertension

Terminated·VVA Office of Research and Development·Phase 2·NCT03810911·27 enrolled

Neurocognitive1 trial

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Completed·NNICHD Neonatal Research Network·Phase 3·NCT03169881·650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Darbepoetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Darbepoetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Darbepoetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Darbepoetin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2031

Trials by Indication[1]

Myelodysplastic Syndromes2 trials

Cirrhosis2 trials

Dialysis1 trial

Liver Transplant1 trial

Nephropathy1 trial

Hypertension1 trial

Neurocognitive1 trial

References

Drug Info

Quick Facts

Related News